Target Name: SNHG8
NCBI ID: G100093630
Review Report on SNHG8 Target / Biomarker Content of Review Report on SNHG8 Target / Biomarker
Other Name(s): small nucleolar RNA host gene 8 | Small nucleolar RNA host gene 8, transcript variant 1 | NCRNA00060 | SNHG8 variant 1 | LINC00060

The Role of SNHG8: A Rising Star in Drug Target and Biomarker Research

The quest for novel drug targets and biomarkers to diagnose and treat various diseases has intensified in recent years. Among the various players taking center stage in this research, the non-coding RNA, Small Nucleolar RNA Host Gene 8 (SNHG8), has emerged as a promising candidate. The discovery of SNHG8 has opened up new avenues of investigation, paving the way for potential therapeutic interventions and diagnostic tools. In this article, we delve into the multifaceted world of SNHG8, exploring its role as a drug target and potential biomarker.

The Genesis of SNHG8

SNHG8, located on chromosome 12q24.31, was initially identified as a novel long non-coding RNA (lncRNA) through high-throughput sequencing technologies. LncRNAs, unlike their protein-coding counterparts, do not encode proteins but regulate gene expression through diverse mechanisms. SNHG8 displays tissue-specific expression patterns, making it an interesting candidate for further exploration.

SNHG8 as a Drug Target

One of the primary focuses of drug discovery research is to identify targets that can modulate disease-associated pathways effectively. SNHG8 has been shown to participate in several biological processes and has been implicated in various diseases, making it an attractive target for therapeutic interventions.

Cancer: A Promising Realm for SNHG8

Cancer is a complex and heterogeneous disease, and identifying effective therapeutic targets continues to be a challenge. However, emerging evidence suggests that SNHG8 plays a crucial role in cancer progression. Several studies have demonstrated aberrant expression of SNHG8 in various cancer types, including breast, lung, colorectal, and hepatocellular carcinomas.

SNHG8 has been found to influence cancer cell proliferation, apoptosis, migration, and invasion, indicating its potential as a therapeutic target. For instance, in breast cancer, SNHG8 promotes cell proliferation and inhibits apoptosis through the modulation of specific signaling pathways. Targeting SNHG8 could potentially lead to the development of novel therapies to combat cancer.

SNHG8 as a Radiosensitizer

Radiation therapy is a widely used treatment modality for cancer. However, radioresistance remains a significant obstacle in achieving optimal therapeutic outcomes. Recent studies have revealed the potential of SNHG8 as a radiosensitizer, enhancing the efficacy of radiation therapy.

SNHG8 promotes DNA damage repair through various mechanisms, leading to increased radioresistance. Inhibition of SNHG8 has shown promising results in sensitizing cancer cells to radiation, suggesting its potential as an adjunctive therapy in the field of radiotherapy.

SNHG8 as a Potential Biomarker

Biomarkers play a crucial role in the early diagnosis, prognosis, and monitoring of diseases. SNHG8 has shown promise as a potential biomarker due to its dysregulated expression in various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders.

In the realm of cancer, SNHG8 levels have been associated with tumor size, lymph node metastasis, and overall survival. Its high expression in patients has been correlated with poorer prognosis and shorter survival rates. Monitoring SNHG8 levels in bodily fluids such as blood and urine may provide valuable diagnostic and prognostic information, facilitating early detection and personalized treatment strategies.

Fulfilling the Potential: Challenges and Future Directions

While the discovery of SNHG8 has shed light on its immense potential as a drug target and biomarker, numerous challenges lie ahead. Elucidating the precise mechanisms by which SNHG8 operates is crucial for exploiting it therapeutically. Additionally, developing effective delivery systems for targeted therapy and establishing standardized protocols for clinical implementation of SNHG8 as a biomarker are necessary steps to realize its full potential.

In conclusion, SNHG8 has emerged as a rising star in drug target and biomarker research. Its multifaceted roles in cancer progression, particularly as a radiosensitizer, and its dysregulated expression in various diseases make it an exciting area of investigation. Focusing on SNHG8 may provide researchers with novel insights into disease pathogenesis and potentially uncover new therapeutic strategies while revolutionizing disease diagnosis and patient management.

1. Xie Y, et al. (2020). Long non-coding RNA Small Nucleolar RNA Host Gene 8 (SNHG8) promotes proliferation and inhibits apoptosis of breast cancer cells by targeting the STAT1/BAI1 signaling pathway. Med Sci Monit. 26:e921698.
2. Yang G, et al. (2020). Long non-coding RNA SNHG8 promotes the progression of breast cancer by sponging microRNA-378a-3p and consequently upregulating PARP-1. Cell Mol Biol Lett. 25:36.
3. Li N, et al. (2017). lncRNA SNHG8 is identified as a key regulator of the proliferation, apoptosis, and migration of HUVECs through targeting miR-185-5p/IGF1R axis. Cell Cycle. 16(23):2395-2406.
4. Shi J, et al. (2018). Knockdown of long non-coding RNA SNHG8 inhibits growth and invasion of hepatocellular carcinoma cells through up-regulating miR-326. Oncotarget. 9(23):16715-16723.

Protein Name: Small Nucleolar RNA Host Gene 8

The "SNHG8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNHG8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

SNORA11B | SNORA11E | SNORA38B | SNORA70B | SNORA70C | SNORA70E | SNORA70F | SNORA70G | SNORA80B | SNORA84 | SNORD111B | SNORD115-10 | SNORD115-11 | SNORD115-12 | SNORD115-13 | SNORD115-14 | SNORD115-15 | SNORD115-16 | SNORD115-17 | SNORD115-18 | SNORD115-19 | SNORD115-2 | SNORD115-20 | SNORD115-21 | SNORD115-22 | SNORD115-24 | SNORD115-25 | SNORD115-27 | SNORD115-28 | SNORD115-29 | SNORD115-3 | SNORD115-30 | SNORD115-31 | SNORD115-32 | SNORD115-33 | SNORD115-36 | SNORD115-37 | SNORD115-38 | SNORD115-39 | SNORD115-4 | SNORD115-40 | SNORD115-41 | SNORD115-42 | SNORD115-43 | SNORD115-44 | SNORD115-48 | SNORD115-5 | SNORD115-6 | SNORD115-7 | SNORD115-8 | SNORD115-9 | SNORD116-1 | SNORD116-10 | SNORD116-11 | SNORD116-12 | SNORD116-13 | SNORD116-14 | SNORD116-15 | SNORD116-16 | SNORD116-17 | SNORD116-18 | SNORD116-2 | SNORD116-20 | SNORD116-21 | SNORD116-22 | SNORD116-23 | SNORD116-24 | SNORD116-25 | SNORD116-26 | SNORD116-27 | SNORD116-28 | SNORD116-29 | SNORD116-3 | SNORD116-4 | SNORD116-5 | SNORD116-6 | SNORD116-7 | SNORD116-8 | SNORD116-9 | SNORD119 | SNORD11B | SNORD121A | SNORD121B | SNORD123 | SNORD124 | SNORD125 | SNORD126 | SNORD12B | SNORD19B | SNORD58C | SNRK-AS1 | SNRPCP3 | SNRPEP4 | SNRPF-DT | SNRPGP10 | SNTG1 | SNTG2 | SNTG2-AS1 | SNUPN | SNX18P23